Table 1.
MASP-1, MASP-2, MASP-3, MAp-44, and MAp-19 serum concentrations in patients with cervical lesions and cancer.
| CIN-1 (n = 52) | CIN-2 (n = 73) | CIN-3 (n = 141) | Ca (n = 78) | p | |
|---|---|---|---|---|---|
| MASP-1 (ng/mL) median (IQR) | 5,636 (3,758–8,129) |
6,083 (3,823–8,422) |
4,714 (3,319–6,839) |
6,435 (3,971–9,074) |
0.012 |
| MASP-2 (ng/mL) median (IQR) | 232.2 (163–386) |
264.5 (190–418) |
282.5 (204–410) |
354.4 (234–570) |
0.001 |
| MASP-3 (ng/mL) median (IQR) | 3,846 (2,750–5,212) |
3,984 (3,181–5,180) |
4,053 (2,947–5,071) |
3,954 (2,705–5,142) |
0.829 |
| Map-44 (ng/mL) median (IQR) | 1,695 (1,343–2,248) |
1,787 (1,471–2,271) |
1,710 (1,434–2,099) |
1,866 (1,598–2,171) |
0.246 |
| Map-19 (ng/mL) median (IQR) | 214.2 (152–289) |
239.3 (162–318) |
234.4 (167–298) |
309.9 (219–487) |
0.025 |
IQR, Interquartile range; CIN, Cervical intraepithelial neoplasia; Ca, Cancer.